Ann Falsey, MD
Enriched profileProfessor of Medicine, Division of Infectious Diseases, and Co-Director, Vaccine and Treatment Evaluation Unit (VTEU) · University of Rochester Medical Center
Ann Falsey is Professor of Medicine, Division of Infectious Diseases, and Co-Director, Vaccine and Treatment Evaluation Unit (VTEU) at University of Rochester Medical Center. OpenAlex indexes 374 publications with 30,161 citations (h-index 84); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Infectious Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Ann Falsey, MD, is Professor of Medicine, Division of Infectious Diseases, and Co-Director, Vaccine and Treatment Evaluation Unit (VTEU) at University of Rochester Medical Center / School of Medicine and Dentistry. The public record shows 374 publications with 30,161 citations (h-index 84), centered on Respiratory viral infections research, Pneumonia and Respiratory Infections, Influenza Virus Research Studies. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 11 companies, 5 NIH-funded awards (2005–2026).
- Most recent indexed publication: 2026 · The Journal of infectious diseases
- Top research focus: Respiratory viral infections research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 226.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Standing member
NIH Center for Scientific Review "Clinical Studies and Field Research" study section
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
Sponsor: University of Rochester
- Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections
Sponsor: University of Rochester
Industry payments
Updated 27 Aug 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI PASTEUR INC.Program year20255 payments$27,954openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20259 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Penicillins with extended spectrum100%Amoxicillin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
5 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
University of Rochester
FY2026$400,801UM1AI148450 - University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
University of Rochester
FY2025$865,920UM1AI148450 - University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
University of Rochester
FY2024$932,430UM1AI148450
Congress activity
Updated 27 Aug 2026
2 congress contributions (2015–2017) across ASCO per OpenAlex. The most recent:
- Randomized study comparing high-dose (HD) influenza vaccine to standard-dose (SD) influenza vaccine in patients with breast cancer age < 65 receiving chemotherapy.
ASCO Annual Meeting
ASCO2017Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Discriminating Bacterial from Nonbacterial Lower Respiratory Tract Infection within Clinical Subgroups of Hospitalized Adults.
The Journal of infectious diseases
Article2026 - Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345.
Clinical infectious diseases
Clinical Trial2026 - Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus.
Clinical infectious diseases
Article2026 - Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years.
Clinical infectious diseases
Clinical Trial2026 - A four-gene signature from blood to exclude bacterial etiology of lower respiratory tract infection in adults.
Nature communications
Article2025
Most-cited works
by citation count (OpenAlex)- 01Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesArticle2,739 citations2020
- 02Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsArticle2,238 citations2005
- 03Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsArticle1,591 citations2020
- 04Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older AdultsArticle655 citations2023
- 05Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infectionsArticle649 citations2017
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ann-falsey-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Ann-R-Falsey-39077255
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/ann-falsey-34aa357
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/CGqCeQPBnn4
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
- B.S. in Biology
Providence College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗ - Board Certified
Internal Medicine (Infectious Disease), American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Editorial & leadership roles
journal and society appointments- Steering committee member
Global Influenza Initiative
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗ - Member
Infectious Diseases Society of America (IDSA)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗ - Member
American Society for Virology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Awards & honors
honors on the public record- John F. Enders Distinguished Lecture in Medical Virology
awarded by the Infectious Diseases Society of America (IDSA), delivered at IDWeek ("Beyond Bronchiolitis: Respiratory Syncytial Virus in Adults")
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rochesterregional.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urmc.rochester.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Louis Constine, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Edward Messing, MD
University of Rochester Medical Center
Paul Barr, MD
University of Rochester Medical Center